| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $152.00 $214.00 $728.00 $2601.00 $10965.00 $21838.00 $41096.00 | 5 | |
GPCR antagonist that could potentially inhibit OR4F4 by preventing G-protein activation and subsequent signaling. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Angiotensin II receptor antagonist that could potentially inhibit OR4F4 by affecting similar GPCR signaling pathways. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Non-selective beta-adrenergic blocker that could potentially modulate GPCR signaling pathways, thus inhibiting OR4F4. | ||||||
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $63.00 $265.00 | 21 | |
CYP3A4 inhibitor that could potentially affect metabolic pathways involved in GPCR signaling, thus inhibiting OR4F4. | ||||||
Itraconazole | 84625-61-6 | sc-205724 sc-205724A | 50 mg 100 mg | $78.00 $142.00 | 23 | |
CYP3A4 inhibitor that could potentially alter GPCR-associated metabolic pathways, thus inhibiting OR4F4. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Adenylyl cyclase activator that could potentially modulate the cAMP pathway often involved in GPCR signaling, thus inhibiting OR4F4. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $451.00 | 3 | |
G-protein inhibitor that could prevent G-protein coupling and signaling, thus inhibiting OR4F4. | ||||||
AMI-1, sodium salt | 20324-87-2 | sc-205928 sc-205928A | 5 mg 25 mg | $114.00 $398.00 | 2 | |
Adenylyl cyclase inhibitor that could modulate cAMP production, impacting GPCR signaling and potentially inhibiting OR4F4. | ||||||